Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Global resistance of Neisseria gonorrhoeae: when theory becomes reality.

Lewis DA.

Curr Opin Infect Dis. 2014 Feb;27(1):62-7. doi: 10.1097/QCO.0000000000000025. Review.

PMID:
24275696
2.
3.

Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins.

Tapsall JW.

Curr Opin Infect Dis. 2009 Feb;22(1):87-91. doi: 10.1097/QCO.0b013e328320a836. Review.

PMID:
19532086
4.

Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance.

Cole MJ, Spiteri G, Jacobsson S, Pitt R, Grigorjev V, Unemo M; Euro-GASP Network..

BMC Infect Dis. 2015 Aug 11;15:321. doi: 10.1186/s12879-015-1013-x.

5.

Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):873-7.

6.

Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan.

Shimuta K, Watanabe Y, Nakayama S, Morita-Ishihara T, Kuroki T, Unemo M, Ohnishi M.

BMC Infect Dis. 2015 Sep 17;15:378. doi: 10.1186/s12879-015-1110-x.

7.

Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution.

Wind CM, de Vries HJ, van Dam AP.

Int J Antimicrob Agents. 2015 Mar;45(3):305-8. doi: 10.1016/j.ijantimicag.2014.10.020. Epub 2014 Dec 2.

8.

Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011.

Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M.

BMC Infect Dis. 2013 Jan 25;13:40. doi: 10.1186/1471-2334-13-40.

9.

Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae.

Tapsall JW, Ndowa F, Lewis DA, Unemo M.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):821-34. doi: 10.1586/eri.09.63. Review.

PMID:
19735224
10.

Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011.

Hottes TS, Lester RT, Hoang LM, McKay R, Imperial M, Gilbert M, Patrick D, Wong T, Martin I, Ogilvie G.

Sex Transm Dis. 2013 Jan;40(1):46-51. doi: 10.1097/OLQ.0b013e31827bd64c.

PMID:
23250301
11.

Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe.

Cole MJ, Spiteri G, Chisholm SA, Hoffmann S, Ison CA, Unemo M, Van de Laar M.

Euro Surveill. 2014 Nov 13;19(45):20955.

12.

Current and future treatment options for gonorrhoea.

Ison CA, Deal C, Unemo M.

Sex Transm Infect. 2013 Dec;89 Suppl 4:iv52-6. doi: 10.1136/sextrans-2012-050913. Epub 2013 Oct 8. Review.

PMID:
24106339
13.

Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure.

Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M.

J Antimicrob Chemother. 2013 Jun;68(6):1267-70. doi: 10.1093/jac/dkt034. Epub 2013 Feb 14.

PMID:
23416957
14.

The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting.

Whiley DM, Goire N, Lahra MM, Donovan B, Limnios AE, Nissen MD, Sloots TP.

J Antimicrob Chemother. 2012 Sep;67(9):2059-61. doi: 10.1093/jac/dks188. Epub 2012 May 17. Review.

PMID:
22604449
15.

Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone.

Starnino S; GASP-LAC Working Group., Galarza P, Carvallo ME, Benzaken AS, Ballesteros AM, Cruz OM, Hernandez AL, Carbajal JL, Borthagaray G, Payares D, Dillon JA.

Sex Transm Dis. 2012 Oct;39(10):813-21.

PMID:
23001269
16.
17.

High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P.

Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. doi: 10.1128/AAC.05760-11. Epub 2011 Dec 12.

18.

Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?

Lewis DA.

Sex Transm Infect. 2015 Jun;91(4):234-7. doi: 10.1136/sextrans-2014-051731. Epub 2015 Apr 24. Review.

PMID:
25911525
19.

In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?

Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra MM, Tapsall JW.

Antimicrob Agents Chemother. 2012 Jul;56(7):3603-9. doi: 10.1128/AAC.00326-12. Epub 2012 Apr 30.

20.

Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.

Whiley DM, Jacobsson S, Tapsall JW, Nissen MD, Sloots TP, Unemo M.

J Antimicrob Chemother. 2010 Dec;65(12):2543-7. doi: 10.1093/jac/dkq377. Epub 2010 Oct 12.

PMID:
20940180

Supplemental Content

Support Center